Silence Therapeutics Reports Narrower Q1 Loss, Awaits Key Phase 2 Data
Event summary
- Q1 2026 net loss narrowed to $15.0M from $28.5M YoY, with R&D expenses down 56% due to completed Phase 3 readiness for zerlasiran.
- Cash position stands at $70.1M as of March 31, 2026, with $0.4M in collaboration revenue from AstraZeneca.
- Phase 2 topline results for divesiran in polycythemia vera (PV) expected in August 2026.
- Phase 1 data for SLN312 (AZD1705) in dyslipidemia to be presented at EAS Congress in May 2026.
The big picture
Silence Therapeutics is navigating a critical phase in its development, with upcoming clinical readouts that could significantly impact its valuation. The company's focus on siRNA therapies aligns with broader industry trends toward precision medicine, but its ability to secure partnerships and funding will be key to sustaining momentum. The narrowing of its net loss and reduced R&D expenses reflect strategic cost management, but the path to profitability remains uncertain.
What we're watching
- Clinical Milestones
- Whether divesiran's Phase 2 results in August 2026 will validate its potential as a first-in-class siRNA therapy for polycythemia vera.
- Financial Sustainability
- The pace at which Silence Therapeutics can extend its cash runway beyond the current $70.1M position.
- Pipeline Progress
- How SLN312's Phase 1 data will position it against competitors in the dyslipidemia market.
Related topics